RePORT ⟩ RePORTER

Project Details

Clinical Support Services for the NIAMS Intramural Research Program

Project Number1ZIDAR041180-14 NIDB ANNUAL REPORT

Contact PI/Project LeaderCOLBERT, ROBERT

Awardee OrganizationNATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

Description

Abstract Text

This project has provided research infrastructure support for the following clinical protocols as noted: 03-AR-0173: Studies of the Natural History, Pathogenesis and Outcome in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis 11-AR-0223: Studies on the Natural History and Pathogenesis of Spondyloarthritis 12-AR-8001: Compassionate Use Treatment Protocol 14V-MC-JAGA Treatment of Autoinflammatory Syndromes Expected to Benefit from JAK 1/2 Inhibition 18-AR-0081: Investigation of the Natural History, Genetics and Pathophysiology of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still's Disease and Related Inflammatory Conditions 91-AR-0196: Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases 00-AR-0222: Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions 01-AR-0227: Natural History of Rheumatic Disease in Minority Communities 14-AR-0200: Studies of the Natural History, Pathogenesis and Outcome of Idiopathic Systemic Vasculitis 15-AR-0165: Study of the Natural History, Pathogenesis and Outcome of Melorheostosis-a Rare Osteosclerotic Disease 07-AR-0146: Analysis of Stored Identified Specimens from Patients Enrolled in Protocol Number 98-AR-0150 99-AR-0004: Molecular Basis of Primary Immunodeficiencies 15-AR-0185: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies 15-AR-0060: The Role of PPAR-gamma Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE). 94-AR-0066: Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE) 03-AR-0131: Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study 04-AR-0205: Progression of Spinal Fusion in Ankylosing Spondylitis 13-AR-0056: Stopping Anti-TNF Agents in Rheumatoid Arthritis (STARA) Trial 15-AR-N010: Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries 96-AR-0102: Standard Care Dermatology; Evaluation and treatment of subjects with dermatologic diseases 18-AR-0035: Topical ruxolitinib in cGVHD; Phase II study of topical ruxolitinib for cutaneious chronic graft versus host disease (cGVHD) 13-AR-0071: Anakinra in Pustular Dermatoses; A phase 2 study of anakinra in inflammatory pustular dermatoses: evaluation of therapeutic efficacy and validation of pathogenic mechanisms 20-AR-0046: Phase 2 Zilucoplan in IMNM (Andrew Mammen); A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of Zilucoplan in subjects with immune-mediated necrotizing myopathy 000207: SAD-COVID: The natural history of coronavirus disease (COVID-19) in systemic autoimmune diseases; an observational prospective study 20-AR-0032: Glucocorticoid Genomics in SLE; Genomic effects of glucocorticoids in patients with systemic lupus erythematosus 13-AR-0005: STOP LUPUS: A phase 1b, randomized, double-blind, placebo controlled study with an open label extension to evaluate the safety and tolerability of Omalizumab, a humanized IgG1 monoclonal antibody in patients with lupus (STOP LUPUS)

Public Health Relevance Statement

Data not available.

NIH Spending Category

ArthritisAutoimmune DiseaseClinical ResearchClinical Trials and Supportive ActivitiesHealth ServicesLupusMinority HealthPatient SafetyPediatricRare DiseasesRheumatoid ArthritisWomen's Health

Project Terms

Adult-Onset Still's DiseaseAgonistAmbulatory Care FacilitiesAnkylosing spondylitisAppointments and SchedulesArthritisAutoimmuneBlood VesselsCOVID-19ClinicalClinical ProtocolsClinical ResearchContractsDatabasesDermatologicDermatologyDermatomyositisDiseaseDouble-Blind MethodEnrollmentEvaluationFellowshipFrequenciesFunctional disorderGeneticGenetic DeterminismGenomicsGlucocorticoidsHospitalistsIgG1ImmuneInflammatoryInfrastructureInstitutional Review BoardsIntramural Research ProgramInvestigationJanus kinaseLongitudinal StudiesLupusMediatingMedicalMedicareMelorheostosisMolecularMonoclonal AntibodiesMyopathyNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNatural HistoryNeighborhood Health CenterNurse PractitionersNursing ResearchOralOrthopedic ProceduresOutcomePPAR gammaPathogenesisPathogenicityPatientsPeroxisome Proliferator-Activated ReceptorsPhasePhase Ib Clinical TrialPhysiciansPreparationPreventionProspective StudiesProtocols documentationRandomizedResearch ActivityResearch AssistantResearch InfrastructureResearch SupportRheumatismRheumatoid ArthritisRheumatologyRoleSafetyServicesSeveritiesSpecimenSpinal FusionSpondylarthritisSyndromeSystemic Lupus ErythematosusTNF geneTraining ProgramsTranslational ResearchTravelTreatment ProtocolsUnited States National Institutes of HealthVasculitisanakinraautoinflammatorybeneficiarychronic graft versus host diseaseclinical centercongenital immunodeficiencycoronavirus diseasecostefficacy validationimmunoregulationkinase inhibitorminority communitiesomalizumabopen labelphase 2 studyplacebo controlled studyprogramsskin disorderstandard caresystemic autoimmune diseasesystemic juvenile idiopathic arthritistherapeutic evaluation

Details

Contact PI/ Project Leader

Name

COLBERT, ROBERT

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

City

Country

UNITED STATES

Department Type

Unavailable

Organization Type

Unavailable

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2021

Award Notice Date

Administering Institutes or Centers

National Institute of Arthritis and Musculoskeletal and Skin Diseases

CFDA Code

DUNS Number

UEI

Project Start Date

Project End Date

Budget Start Date

Budget End Date

Project Funding Information for 2021

Total Funding

$10,454,762

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2021	National Institute of Arthritis and Musculoskeletal and Skin Diseases	$10,454,762

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES	$1,045,476
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES	$10,454,762	Arthritis; Autoimmune Disease; Clinical Research; Clinical Trials and Supportive Activities; Health Services; Lupus; Patient Safety; Pediatric; Rare Diseases; Rheumatoid Arthritis; Women's Health

Sub Projects

No Sub Projects information available for 1ZIDAR041180-14

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 1ZIDAR041180-14

Patents

No Patents information available for 1ZIDAR041180-14

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1ZIDAR041180-14

Clinical Studies

No Clinical Studies information available for 1ZIDAR041180-14

News and More

Section Menu